Spain to India: Syringe Import Trade Route

The Spain to India Syringe corridor is one of India's established pharmaceutical import routes from Spain, with 15 shipments documented worth a combined $21.6M USD. The route is dominated by M /S LABORATORIOS FARMALAN S.A , which alone accounts for roughly 99% of all import value, reflecting the consolidated nature of Spain's syringe export sector.

Across 7 active Spain suppliers, the average shipment value stands at $1.4M USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 83% of all shipments, consistent with syringe's non-urgent bulk-order profile.

Shipment activity peaks during July–September, with an average transit time of 23 days port-to-port. The route has recorded an annual growth rate of 30.1%, placing it at rank #8 among India's top syringe import origins globally.

On the Indian buyer side, key Indian importers include CHEMO INDIA FORMULATION PRIVATE LIMITED , ZYDUS LIFESCIENCES LIMITED , LAMBDA THERAPEUTIC RESEARCH LIMITED and 1 others. CHEMO INDIA FORMULATION PRIVATE LIMITED is the single largest Indian importer with 5 shipments valued at $21.5M USD.

India's syringe imports from Spain are driven primarily by a handful of large-scale Spain manufacturers. M /S LABORATORIOS FARMALAN S.A with 1 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 7 active exporters signals a competitive but concentrated market — Indian buyers benefit from Spain supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — M /S LABORATORIOS FARMALAN S.A , M/S UNIVERSAL FARMA, S.L. , ABACUS MEDICINE PHARMA SERVICES LTD. — together account for 100% of total trade value on this route. The average shipment value of $1.4M USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as (lanreotide) 120 mg solution for injection in a pre-filled syringe (120mg) (tl no: sw/nd/ct-17/2024/000001756) for r&d p and (lanreotide) 120 mg solution for injection in a pre-filled syringe (120mg) (tl no: sw/nd/ct-17/2024/000001755) for r&d p , suggesting that Indian buyers tend to consolidate orders across related product lines from the same Spain supplier.

On the buying side, CHEMO INDIA FORMULATION PRIVATE LIMITED is the largest importer with 5 shipments worth $21.5M USD — representing 100% of all syringe imports from Spain on this route.